A Phase 2 trial studied retatrutide in participants with obesity
Retatrutide — Evidence
Clinical trials and publications sourced from ClinicalTrials.gov, PubMed, and FDA. Updated hourly by the automated crawler.
Claims and sources (1)
Verified evidence (1)
Retatrutide in Participants With Obesity
Phase 2 · COMPLETED · Started 2021
Registered studies (34)
From the ClinicalTrials.gov record captured for this substance. Registration is not evidence of approval, efficacy, or safety.
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight
To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants
A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia
A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus
Body Composition and Exercise to Prevent Muscle Loss With GLP1 Agonist Treatment
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)
A Study of LY3437943 in Healthy Participants With a High Body Mass Index
A Study of LY3437943 in Participants With Impaired and Normal Liver Function
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee
A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants
A Study of LY3437943 in Chinese Participants With Obesity Or Overweight
A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function
A Study of LY3437943 in Participants With Type 2 Diabetes
A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)
A Study of LY3437943 in Participants Who Have Obesity or Are Overweight
A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants
A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)
Provide Pre-approval Expanded Access of LY3437943
PubMed (1)
Retatrutide and the urinary tract infection signal: Is the answer hidden in timing?
European journal of internal medicine · 2026 Jul 23 · DOI: 10.1016/j.ejim.2026.107099